Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control

Diabetes Technology and Therapeutics

Volumn 16, Issue 4, 2014, Pages 198-203

  Šoupal, Jan ^a   Škrha, Jan ^a   Fajmon, Martin ^a   Horová, Eva ^a   Mráz, Miloš ^a   Prázný, Martin ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C PEPTIDE; CREATININE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD GLUCOSE METER; BLOOD GLUCOSE MONITORING; BODY MASS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; DIABETIC MICROANGIOPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCEMIC VARIABILITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; MALE; MEAN AMPLITUDE OF GLYCEMIC EXCURSION; METABOLIC PARAMETERS; MICROALBUMINURIA; MIDDLE AGED; MYDRIASIS; OPHTHALMOSCOPY; OUTPATIENT; PERCEPTIVE THRESHOLD; PRIORITY JOURNAL; SELF MONITORING; SENSORY NEUROPATHY; VIBRATION SENSE; ALBUMINURIA; AMBULATORY MONITORING; ANALYSIS OF VARIANCE; BLOOD; COMPLICATION; DIABETIC ANGIOPATHIES; METABOLISM; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; RISK; RISK ASSESSMENT; VIBRATION;

ADULT; ALBUMINURIA; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; MONITORING, AMBULATORY; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; VIBRATION;

EID: 84896374662     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2013.0205     Document Type: Article

References (29)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. The Diabetes Control and Complications Trial (DCCT) Research Group. N Engl J Med 1993;329:977-986.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
3. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412. (Pubitemid 30609442)
4. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic ne-phropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. DCCT/EDIC Research Group. JAMA 2003;290:2159-2167.
5. Hirsch IB, Brownlee M: Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 2005;19:178-181. (Pubitemid 40615551)
6. Hanefeld M: Postprandial hyperglycaemia: noxious effects on the vessel wall. Int J Clin Pract Suppl 2002;129:45-50.
7. Monnier L, Colette C: Glycemic variability: should we and can we prevent it? Diabetes Care 2008;31(Suppl 2):S150-S154.
8. Siegelaar SE, Holleman F, Hoekstra JBL, DeVries JH: Glucose variability; does it matter? Endocr Rev 2010;31:171-182.
9. Brownlee M, Hirsch IB: Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006;295:1707-1708.
10. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-821.
11. Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-1625. (Pubitemid 40770750)
12. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M: Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008;205: 2409-2417.
13. Ceriello A, Esposito K, Piconi L, Ihnat M, Thorpe J, Testa R, Bonfigli AR, Giugliano D: Glucose "peak" and glucose "spike": impact on endothelial function and oxidative stress. Diabetes Res Clin Pract 2008;82:262-267.
14. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglyce-mia in patients with type 2 diabetes. JAMA 2006;295:1681-1687.
15. Siegelaar SE, Barwari T, Kulik W, Hoekstra JB, DeVries JH: No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients. J Diabetes Sci Technol 2011;5:86-92.
16. Wentholt IM, Kulik W, Michels RP, Hoekstra JB, DeVries JH: Glucose fluctuations and activation of oxidative stress in type 1 diabetes patients. Diabetologia 2008;51:183-190. (Pubitemid 50002199)
17. Snell-Bergeon JK, Roman R, Rodbard D, Garg S, Maahs DM, Schauer IE, Bergman BC, Kinney GL, Rewers M: Glycaemic variability and coronary artery calcium: The Coronary Artery Calcification in Type 1 Diabetes Study. Diabet Med 2010;27:1436-1442.
18. Bragd J, Adamson U, Bäcklund LB, Lins PE, Moberg E, Oskarsson P: Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? Diabetes Metab 2008;34:612-616.
19. Kilpatrick ES, Rigby AS, Atkin SL: Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 2009;32:1901-1903.
20. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN; DCCT/EDIC Research Group: Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial-revisited. Diabetes 2008; 57:995-1001.
21. Baghurst PA, Rodbard D, Cameron FJ: The minimum frequency of glucose measurements from which glycemic variation can be consistently assessed. J Diabetes Sci Technol 2010;4:1382-1385.
22. Bakker AJ: Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999;22:307-313. (Pubitemid 29056927)
23. Boulton AJ, Armstrong DG, Albert SF, Frykberg RG, Hell-man R, Kirkman MS, Lavery LA, Lemaster JW, Mills JL Sr, Mueller MJ, Sheehan P, Wukich DK; AmericanDiabetes Association; American Association of Clinical Endo-crinologists: Comprehensive foot examination and risk assessment: a report of the Task Force of the Foot Care Interest Group of the American Diabetes Association, with endorsement by the American Association of Clinical En-docrinologists. Diabetes Care 2008;31:1679-1685.
24. Rodbard D: Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther 2009;11(Suppl 1):S-55-S-67.
25. Greven WL, Beulens JW, Biesma DH, Faiz S, de Valk HW: Glycemic variability in inadequately controlled type 1 diabetes and type 2 diabetes on intensive insulin therapy: a cross-sectional, observational study. Diabetes Technol Ther 2010;12:695-699.
26. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gate-wood LC, Taylor WF: Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970; 19:644-655.
27. Nalysnyk L, Hernandez-Medina M, Krishnarajah G: Gly-caemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 2010;12:288-298.
28. Kilpatrick ES, Rigby AS, Atkin SL: The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006;29:1486-1490. (Pubitemid 44127568)
29. Siegelaar SE, Kilpatrick ES, Rigby AS, Atkin SL, Hoekstra JB, Devries JH: Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 2009;52: 2229-2232.